{"transactions":[{"id":689361,"issuer":{"id":5423,"kind":"organization","name":"BlossomHill Therapeutics, Inc."},"owners":[{"id":24161,"kind":"person","name":"GORDON CARL L","position":1,"cik":"0001282930","reported_name":"GORDON CARL L","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Series B Preferred Stock","published_at":"2026-08-12T20:46:16.000Z","date":"2026-08-10","kind":"exercise","planned":false,"acquired":false,"shares":1049283,"price":0,"value":0.0,"ownership":{"direct":false,"nature":"See footnotes"},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"Each share of Series A Preferred Stock and Series B Preferred Stock (together, the \"Preferred Stock\") automatically converted into 1 share of the Issuer's Common Stock upon the closing of the Issuer's initial public offering on August 10, 2026 without payment of consideration. The Preferred Stock has no expiration date."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"Each share of Series A Preferred Stock and Series B Preferred Stock (together, the \"Preferred Stock\") automatically converted into 1 share of the Issuer's Common Stock upon the closing of the Issuer's initial public offering on August 10, 2026 without payment of consideration. The Preferred Stock has no expiration date."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F1","text":"Each share of Series A Preferred Stock and Series B Preferred Stock (together, the \"Preferred Stock\") automatically converted into 1 share of the Issuer's Common Stock upon the closing of the Issuer's initial public offering on August 10, 2026 without payment of consideration. The Preferred Stock has no expiration date."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"These securities are held directly by OrbiMed Private Investments VIII, LP (\"OPI VIII\"). OrbiMed Capital GP VIII LLC (\"GP VIII\") is the general partner of OPI VIII. OrbiMed Advisors LLC (\"OrbiMed Advisors\") is the managing member of GP VIII. By virtue of such relationships, GP VIII and OrbiMed Advisors may be deemed to have voting power and investment power over the securities held by OPI VIII and as a result, may be deemed to have beneficial ownership over such securities. OrbiMed Advisors exercises voting and investment power through a management committee comprised of the Reporting Person, W. Carter Neild, and Geoffrey C. Hsu, each of whom disclaims beneficial ownership of the shares held by OPI VIII."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F4","text":"Each of the Reporting Person, OrbiMed Advisors, and GP VIII disclaims beneficial ownership of the securities reported herein for purposes of Rule 16a-1(a) under the Securities Exchange Act of 1934, as amended (the \"Exchange Act\"), except to the extent of its pecuniary interest therein, if any. This report shall not be deemed an admission that any of the Reporting Person, OrbiMed Advisors, or GP VIII is a beneficial owner of such securities for purposes of Section 16 of the Exchange Act, or for any other purpose."}],"balance_after":0,"derivative":{"underlying":"Common Stock","underlying_shares":1049283},"source":{"system":"sec-edgar","filing":"0000947871-26-000785","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/1839970/000094787126000785/ownership.xml","form_type":"4"}},{"id":689360,"issuer":{"id":5423,"kind":"organization","name":"BlossomHill Therapeutics, Inc."},"owners":[{"id":24161,"kind":"person","name":"GORDON CARL L","position":1,"cik":"0001282930","reported_name":"GORDON CARL L","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Series A Preferred Stock","published_at":"2026-08-12T20:46:16.000Z","date":"2026-08-10","kind":"exercise","planned":false,"acquired":false,"shares":1039996,"price":0,"value":0.0,"ownership":{"direct":false,"nature":"See footnotes"},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"Each share of Series A Preferred Stock and Series B Preferred Stock (together, the \"Preferred Stock\") automatically converted into 1 share of the Issuer's Common Stock upon the closing of the Issuer's initial public offering on August 10, 2026 without payment of consideration. The Preferred Stock has no expiration date."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"Each share of Series A Preferred Stock and Series B Preferred Stock (together, the \"Preferred Stock\") automatically converted into 1 share of the Issuer's Common Stock upon the closing of the Issuer's initial public offering on August 10, 2026 without payment of consideration. The Preferred Stock has no expiration date."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F1","text":"Each share of Series A Preferred Stock and Series B Preferred Stock (together, the \"Preferred Stock\") automatically converted into 1 share of the Issuer's Common Stock upon the closing of the Issuer's initial public offering on August 10, 2026 without payment of consideration. The Preferred Stock has no expiration date."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"These securities are held directly by OrbiMed Private Investments VIII, LP (\"OPI VIII\"). OrbiMed Capital GP VIII LLC (\"GP VIII\") is the general partner of OPI VIII. OrbiMed Advisors LLC (\"OrbiMed Advisors\") is the managing member of GP VIII. By virtue of such relationships, GP VIII and OrbiMed Advisors may be deemed to have voting power and investment power over the securities held by OPI VIII and as a result, may be deemed to have beneficial ownership over such securities. OrbiMed Advisors exercises voting and investment power through a management committee comprised of the Reporting Person, W. Carter Neild, and Geoffrey C. Hsu, each of whom disclaims beneficial ownership of the shares held by OPI VIII."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F4","text":"Each of the Reporting Person, OrbiMed Advisors, and GP VIII disclaims beneficial ownership of the securities reported herein for purposes of Rule 16a-1(a) under the Securities Exchange Act of 1934, as amended (the \"Exchange Act\"), except to the extent of its pecuniary interest therein, if any. This report shall not be deemed an admission that any of the Reporting Person, OrbiMed Advisors, or GP VIII is a beneficial owner of such securities for purposes of Section 16 of the Exchange Act, or for any other purpose."}],"balance_after":0,"derivative":{"underlying":"Common Stock","underlying_shares":1039996},"source":{"system":"sec-edgar","filing":"0000947871-26-000785","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1839970/000094787126000785/ownership.xml","form_type":"4"}},{"id":689359,"issuer":{"id":5423,"kind":"organization","name":"BlossomHill Therapeutics, Inc."},"owners":[{"id":24161,"kind":"person","name":"GORDON CARL L","position":1,"cik":"0001282930","reported_name":"GORDON CARL L","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2026-08-12T20:46:16.000Z","date":"2026-08-10","kind":"purchase","planned":false,"acquired":true,"shares":625000,"price":16,"value":10000000.0,"ownership":{"direct":false,"nature":"See footnotes"},"footnotes":[{"field":"shares","element":"transactionShares","label":"F2","text":"Reflects shares of the Issuer's Common Stock purchased in the Issuer's initial public offering."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"These securities are held directly by OrbiMed Private Investments VIII, LP (\"OPI VIII\"). OrbiMed Capital GP VIII LLC (\"GP VIII\") is the general partner of OPI VIII. OrbiMed Advisors LLC (\"OrbiMed Advisors\") is the managing member of GP VIII. By virtue of such relationships, GP VIII and OrbiMed Advisors may be deemed to have voting power and investment power over the securities held by OPI VIII and as a result, may be deemed to have beneficial ownership over such securities. OrbiMed Advisors exercises voting and investment power through a management committee comprised of the Reporting Person, W. Carter Neild, and Geoffrey C. Hsu, each of whom disclaims beneficial ownership of the shares held by OPI VIII."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F4","text":"Each of the Reporting Person, OrbiMed Advisors, and GP VIII disclaims beneficial ownership of the securities reported herein for purposes of Rule 16a-1(a) under the Securities Exchange Act of 1934, as amended (the \"Exchange Act\"), except to the extent of its pecuniary interest therein, if any. This report shall not be deemed an admission that any of the Reporting Person, OrbiMed Advisors, or GP VIII is a beneficial owner of such securities for purposes of Section 16 of the Exchange Act, or for any other purpose."}],"balance_after":2714279,"source":{"system":"sec-edgar","filing":"0000947871-26-000785","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1839970/000094787126000785/ownership.xml","form_type":"4"}},{"id":689358,"issuer":{"id":5423,"kind":"organization","name":"BlossomHill Therapeutics, Inc."},"owners":[{"id":24161,"kind":"person","name":"GORDON CARL L","position":1,"cik":"0001282930","reported_name":"GORDON CARL L","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2026-08-12T20:46:16.000Z","date":"2026-08-10","kind":"exercise","planned":false,"acquired":true,"shares":1049283,"ownership":{"direct":false,"nature":"See footnotes"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Each share of Series A Preferred Stock and Series B Preferred Stock (together, the \"Preferred Stock\") automatically converted into 1 share of the Issuer's Common Stock upon the closing of the Issuer's initial public offering on August 10, 2026 without payment of consideration. The Preferred Stock has no expiration date."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"These securities are held directly by OrbiMed Private Investments VIII, LP (\"OPI VIII\"). OrbiMed Capital GP VIII LLC (\"GP VIII\") is the general partner of OPI VIII. OrbiMed Advisors LLC (\"OrbiMed Advisors\") is the managing member of GP VIII. By virtue of such relationships, GP VIII and OrbiMed Advisors may be deemed to have voting power and investment power over the securities held by OPI VIII and as a result, may be deemed to have beneficial ownership over such securities. OrbiMed Advisors exercises voting and investment power through a management committee comprised of the Reporting Person, W. Carter Neild, and Geoffrey C. Hsu, each of whom disclaims beneficial ownership of the shares held by OPI VIII."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F4","text":"Each of the Reporting Person, OrbiMed Advisors, and GP VIII disclaims beneficial ownership of the securities reported herein for purposes of Rule 16a-1(a) under the Securities Exchange Act of 1934, as amended (the \"Exchange Act\"), except to the extent of its pecuniary interest therein, if any. This report shall not be deemed an admission that any of the Reporting Person, OrbiMed Advisors, or GP VIII is a beneficial owner of such securities for purposes of Section 16 of the Exchange Act, or for any other purpose."}],"balance_after":2089279,"source":{"system":"sec-edgar","filing":"0000947871-26-000785","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1839970/000094787126000785/ownership.xml","form_type":"4"}},{"id":689357,"issuer":{"id":5423,"kind":"organization","name":"BlossomHill Therapeutics, Inc."},"owners":[{"id":24161,"kind":"person","name":"GORDON CARL L","position":1,"cik":"0001282930","reported_name":"GORDON CARL L","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2026-08-12T20:46:16.000Z","date":"2026-08-10","kind":"exercise","planned":false,"acquired":true,"shares":1039996,"ownership":{"direct":false,"nature":"See footnotes"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Each share of Series A Preferred Stock and Series B Preferred Stock (together, the \"Preferred Stock\") automatically converted into 1 share of the Issuer's Common Stock upon the closing of the Issuer's initial public offering on August 10, 2026 without payment of consideration. The Preferred Stock has no expiration date."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"These securities are held directly by OrbiMed Private Investments VIII, LP (\"OPI VIII\"). OrbiMed Capital GP VIII LLC (\"GP VIII\") is the general partner of OPI VIII. OrbiMed Advisors LLC (\"OrbiMed Advisors\") is the managing member of GP VIII. By virtue of such relationships, GP VIII and OrbiMed Advisors may be deemed to have voting power and investment power over the securities held by OPI VIII and as a result, may be deemed to have beneficial ownership over such securities. OrbiMed Advisors exercises voting and investment power through a management committee comprised of the Reporting Person, W. Carter Neild, and Geoffrey C. Hsu, each of whom disclaims beneficial ownership of the shares held by OPI VIII."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F4","text":"Each of the Reporting Person, OrbiMed Advisors, and GP VIII disclaims beneficial ownership of the securities reported herein for purposes of Rule 16a-1(a) under the Securities Exchange Act of 1934, as amended (the \"Exchange Act\"), except to the extent of its pecuniary interest therein, if any. This report shall not be deemed an admission that any of the Reporting Person, OrbiMed Advisors, or GP VIII is a beneficial owner of such securities for purposes of Section 16 of the Exchange Act, or for any other purpose."}],"balance_after":1039996,"source":{"system":"sec-edgar","filing":"0000947871-26-000785","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1839970/000094787126000785/ownership.xml","form_type":"4"}},{"id":689681,"issuer":{"id":5423,"kind":"organization","name":"BlossomHill Therapeutics, Inc."},"owners":[{"id":24290,"kind":"person","name":"ORBIMED ADVISORS LLC","position":1,"cik":"0001055951","reported_name":"ORBIMED ADVISORS LLC","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}},{"id":24291,"kind":"person","name":"OrbiMed Capital GP VIII LLC","position":2,"cik":"0001845804","reported_name":"OrbiMed Capital GP VIII LLC","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Series B Preferred Stock","published_at":"2026-08-12T20:43:49.000Z","date":"2026-08-10","kind":"exercise","planned":false,"acquired":false,"shares":1049283,"price":0,"value":0.0,"ownership":{"direct":false,"nature":"See footnotes"},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"Each share of Series A Preferred Stock and Series B Preferred Stock (together, the \"Preferred Stock\") automatically converted into 1 share of the Issuer's Common Stock upon the closing of the Issuer's initial public offering on August 10, 2026 without payment of consideration. The Preferred Stock has no expiration date."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"Each share of Series A Preferred Stock and Series B Preferred Stock (together, the \"Preferred Stock\") automatically converted into 1 share of the Issuer's Common Stock upon the closing of the Issuer's initial public offering on August 10, 2026 without payment of consideration. The Preferred Stock has no expiration date."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F1","text":"Each share of Series A Preferred Stock and Series B Preferred Stock (together, the \"Preferred Stock\") automatically converted into 1 share of the Issuer's Common Stock upon the closing of the Issuer's initial public offering on August 10, 2026 without payment of consideration. The Preferred Stock has no expiration date."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"These securities are held directly by OrbiMed Private Investments VIII, LP (\"OPI VIII\"). OrbiMed Capital GP VIII LLC (\"GP VIII\") is the general partner of OPI VIII. OrbiMed Advisors LLC (\"OrbiMed Advisors\") is the managing member of GP VIII. By virtue of such relationships, GP VIII and OrbiMed Advisors may be deemed to have voting power and investment power over the securities held by OPI VIII and as a result, may be deemed to have beneficial ownership over such securities. OrbiMed Advisors exercises voting and investment power through a management committee comprised of Carl L. Gordon, W. Carter Neild, and Geoffrey C. Hsu, each of whom disclaims beneficial ownership of the shares held by OPI VIII."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F4","text":"This report on Form 4 is jointly filed by OrbiMed Advisors and GP VIII. Each of the Reporting Persons disclaims beneficial ownership of the securities reported herein for purposes of Rule 16a-1(a) under the Securities Exchange Act of 1934, as amended (the \"Exchange Act\"), except to the extent of its pecuniary interest therein, if any. The Reporting Persons have designated Carl L. Gordon, a member of OrbiMed Advisors, to serve on the Issuer's board of directors. This report shall not be deemed an admission that any of such entity or person is a beneficial owner of such securities for purposes of Section 16 of the Exchange Act, or for any other purpose."}],"balance_after":0,"derivative":{"underlying":"Common Stock","underlying_shares":1049283},"source":{"system":"sec-edgar","filing":"0000947871-26-000784","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/1055951/000094787126000784/ownership.xml","form_type":"4"}},{"id":689680,"issuer":{"id":5423,"kind":"organization","name":"BlossomHill Therapeutics, Inc."},"owners":[{"id":24290,"kind":"person","name":"ORBIMED ADVISORS LLC","position":1,"cik":"0001055951","reported_name":"ORBIMED ADVISORS LLC","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}},{"id":24291,"kind":"person","name":"OrbiMed Capital GP VIII LLC","position":2,"cik":"0001845804","reported_name":"OrbiMed Capital GP VIII LLC","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Series A Preferred Stock","published_at":"2026-08-12T20:43:49.000Z","date":"2026-08-10","kind":"exercise","planned":false,"acquired":false,"shares":1039996,"price":0,"value":0.0,"ownership":{"direct":false,"nature":"See footnotes"},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"Each share of Series A Preferred Stock and Series B Preferred Stock (together, the \"Preferred Stock\") automatically converted into 1 share of the Issuer's Common Stock upon the closing of the Issuer's initial public offering on August 10, 2026 without payment of consideration. The Preferred Stock has no expiration date."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"Each share of Series A Preferred Stock and Series B Preferred Stock (together, the \"Preferred Stock\") automatically converted into 1 share of the Issuer's Common Stock upon the closing of the Issuer's initial public offering on August 10, 2026 without payment of consideration. The Preferred Stock has no expiration date."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F1","text":"Each share of Series A Preferred Stock and Series B Preferred Stock (together, the \"Preferred Stock\") automatically converted into 1 share of the Issuer's Common Stock upon the closing of the Issuer's initial public offering on August 10, 2026 without payment of consideration. The Preferred Stock has no expiration date."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"These securities are held directly by OrbiMed Private Investments VIII, LP (\"OPI VIII\"). OrbiMed Capital GP VIII LLC (\"GP VIII\") is the general partner of OPI VIII. OrbiMed Advisors LLC (\"OrbiMed Advisors\") is the managing member of GP VIII. By virtue of such relationships, GP VIII and OrbiMed Advisors may be deemed to have voting power and investment power over the securities held by OPI VIII and as a result, may be deemed to have beneficial ownership over such securities. OrbiMed Advisors exercises voting and investment power through a management committee comprised of Carl L. Gordon, W. Carter Neild, and Geoffrey C. Hsu, each of whom disclaims beneficial ownership of the shares held by OPI VIII."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F4","text":"This report on Form 4 is jointly filed by OrbiMed Advisors and GP VIII. Each of the Reporting Persons disclaims beneficial ownership of the securities reported herein for purposes of Rule 16a-1(a) under the Securities Exchange Act of 1934, as amended (the \"Exchange Act\"), except to the extent of its pecuniary interest therein, if any. The Reporting Persons have designated Carl L. Gordon, a member of OrbiMed Advisors, to serve on the Issuer's board of directors. This report shall not be deemed an admission that any of such entity or person is a beneficial owner of such securities for purposes of Section 16 of the Exchange Act, or for any other purpose."}],"balance_after":0,"derivative":{"underlying":"Common Stock","underlying_shares":1039996},"source":{"system":"sec-edgar","filing":"0000947871-26-000784","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1055951/000094787126000784/ownership.xml","form_type":"4"}},{"id":689679,"issuer":{"id":5423,"kind":"organization","name":"BlossomHill Therapeutics, Inc."},"owners":[{"id":24290,"kind":"person","name":"ORBIMED ADVISORS LLC","position":1,"cik":"0001055951","reported_name":"ORBIMED ADVISORS LLC","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}},{"id":24291,"kind":"person","name":"OrbiMed Capital GP VIII LLC","position":2,"cik":"0001845804","reported_name":"OrbiMed Capital GP VIII LLC","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2026-08-12T20:43:49.000Z","date":"2026-08-10","kind":"purchase","planned":false,"acquired":true,"shares":625000,"price":16,"value":10000000.0,"ownership":{"direct":false,"nature":"See footnotes"},"footnotes":[{"field":"shares","element":"transactionShares","label":"F2","text":"Reflects shares of the Issuer's Common Stock purchased in the Issuer's initial public offering."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"These securities are held directly by OrbiMed Private Investments VIII, LP (\"OPI VIII\"). OrbiMed Capital GP VIII LLC (\"GP VIII\") is the general partner of OPI VIII. OrbiMed Advisors LLC (\"OrbiMed Advisors\") is the managing member of GP VIII. By virtue of such relationships, GP VIII and OrbiMed Advisors may be deemed to have voting power and investment power over the securities held by OPI VIII and as a result, may be deemed to have beneficial ownership over such securities. OrbiMed Advisors exercises voting and investment power through a management committee comprised of Carl L. Gordon, W. Carter Neild, and Geoffrey C. Hsu, each of whom disclaims beneficial ownership of the shares held by OPI VIII."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F4","text":"This report on Form 4 is jointly filed by OrbiMed Advisors and GP VIII. Each of the Reporting Persons disclaims beneficial ownership of the securities reported herein for purposes of Rule 16a-1(a) under the Securities Exchange Act of 1934, as amended (the \"Exchange Act\"), except to the extent of its pecuniary interest therein, if any. The Reporting Persons have designated Carl L. Gordon, a member of OrbiMed Advisors, to serve on the Issuer's board of directors. This report shall not be deemed an admission that any of such entity or person is a beneficial owner of such securities for purposes of Section 16 of the Exchange Act, or for any other purpose."}],"balance_after":2714279,"source":{"system":"sec-edgar","filing":"0000947871-26-000784","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1055951/000094787126000784/ownership.xml","form_type":"4"}},{"id":689678,"issuer":{"id":5423,"kind":"organization","name":"BlossomHill Therapeutics, Inc."},"owners":[{"id":24290,"kind":"person","name":"ORBIMED ADVISORS LLC","position":1,"cik":"0001055951","reported_name":"ORBIMED ADVISORS LLC","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}},{"id":24291,"kind":"person","name":"OrbiMed Capital GP VIII LLC","position":2,"cik":"0001845804","reported_name":"OrbiMed Capital GP VIII LLC","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2026-08-12T20:43:49.000Z","date":"2026-08-10","kind":"exercise","planned":false,"acquired":true,"shares":1049283,"ownership":{"direct":false,"nature":"See footnotes"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Each share of Series A Preferred Stock and Series B Preferred Stock (together, the \"Preferred Stock\") automatically converted into 1 share of the Issuer's Common Stock upon the closing of the Issuer's initial public offering on August 10, 2026 without payment of consideration. The Preferred Stock has no expiration date."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"These securities are held directly by OrbiMed Private Investments VIII, LP (\"OPI VIII\"). OrbiMed Capital GP VIII LLC (\"GP VIII\") is the general partner of OPI VIII. OrbiMed Advisors LLC (\"OrbiMed Advisors\") is the managing member of GP VIII. By virtue of such relationships, GP VIII and OrbiMed Advisors may be deemed to have voting power and investment power over the securities held by OPI VIII and as a result, may be deemed to have beneficial ownership over such securities. OrbiMed Advisors exercises voting and investment power through a management committee comprised of Carl L. Gordon, W. Carter Neild, and Geoffrey C. Hsu, each of whom disclaims beneficial ownership of the shares held by OPI VIII."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F4","text":"This report on Form 4 is jointly filed by OrbiMed Advisors and GP VIII. Each of the Reporting Persons disclaims beneficial ownership of the securities reported herein for purposes of Rule 16a-1(a) under the Securities Exchange Act of 1934, as amended (the \"Exchange Act\"), except to the extent of its pecuniary interest therein, if any. The Reporting Persons have designated Carl L. Gordon, a member of OrbiMed Advisors, to serve on the Issuer's board of directors. This report shall not be deemed an admission that any of such entity or person is a beneficial owner of such securities for purposes of Section 16 of the Exchange Act, or for any other purpose."}],"balance_after":2089279,"source":{"system":"sec-edgar","filing":"0000947871-26-000784","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1055951/000094787126000784/ownership.xml","form_type":"4"}},{"id":689677,"issuer":{"id":5423,"kind":"organization","name":"BlossomHill Therapeutics, Inc."},"owners":[{"id":24290,"kind":"person","name":"ORBIMED ADVISORS LLC","position":1,"cik":"0001055951","reported_name":"ORBIMED ADVISORS LLC","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}},{"id":24291,"kind":"person","name":"OrbiMed Capital GP VIII LLC","position":2,"cik":"0001845804","reported_name":"OrbiMed Capital GP VIII LLC","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2026-08-12T20:43:49.000Z","date":"2026-08-10","kind":"exercise","planned":false,"acquired":true,"shares":1039996,"ownership":{"direct":false,"nature":"See footnotes"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Each share of Series A Preferred Stock and Series B Preferred Stock (together, the \"Preferred Stock\") automatically converted into 1 share of the Issuer's Common Stock upon the closing of the Issuer's initial public offering on August 10, 2026 without payment of consideration. The Preferred Stock has no expiration date."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"These securities are held directly by OrbiMed Private Investments VIII, LP (\"OPI VIII\"). OrbiMed Capital GP VIII LLC (\"GP VIII\") is the general partner of OPI VIII. OrbiMed Advisors LLC (\"OrbiMed Advisors\") is the managing member of GP VIII. By virtue of such relationships, GP VIII and OrbiMed Advisors may be deemed to have voting power and investment power over the securities held by OPI VIII and as a result, may be deemed to have beneficial ownership over such securities. OrbiMed Advisors exercises voting and investment power through a management committee comprised of Carl L. Gordon, W. Carter Neild, and Geoffrey C. Hsu, each of whom disclaims beneficial ownership of the shares held by OPI VIII."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F4","text":"This report on Form 4 is jointly filed by OrbiMed Advisors and GP VIII. Each of the Reporting Persons disclaims beneficial ownership of the securities reported herein for purposes of Rule 16a-1(a) under the Securities Exchange Act of 1934, as amended (the \"Exchange Act\"), except to the extent of its pecuniary interest therein, if any. The Reporting Persons have designated Carl L. Gordon, a member of OrbiMed Advisors, to serve on the Issuer's board of directors. This report shall not be deemed an admission that any of such entity or person is a beneficial owner of such securities for purposes of Section 16 of the Exchange Act, or for any other purpose."}],"balance_after":1039996,"source":{"system":"sec-edgar","filing":"0000947871-26-000784","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1055951/000094787126000784/ownership.xml","form_type":"4"}},{"id":691971,"issuer":{"id":5423,"kind":"organization","name":"BlossomHill Therapeutics, Inc."},"owners":[{"id":25051,"kind":"person","name":"Schmid John P.","position":1,"cik":"0001478916","reported_name":"Schmid John P.","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2026-08-10T22:35:10.000Z","date":"2026-08-10","kind":"purchase","planned":false,"acquired":true,"shares":6000,"price":16,"value":96000.0,"ownership":{"direct":true},"balance_after":6000,"source":{"system":"sec-edgar","filing":"0001478916-26-000015","document":"form4-08102026_100806.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1839970/000147891626000015/form4-08102026_100806.xml","form_type":"4"}},{"id":691970,"issuer":{"id":5423,"kind":"organization","name":"BlossomHill Therapeutics, Inc."},"owners":[{"id":24161,"kind":"person","name":"GORDON CARL L","position":1,"cik":"0001282930","reported_name":"GORDON CARL L","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Director Stock Option (Right to Buy)","published_at":"2026-08-10T22:33:43.000Z","date":"2026-08-06","kind":"grant","planned":false,"acquired":true,"shares":23904,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"1/36th of the shares subject to the option shall vest in equal monthly installments over a three year period following August 6, 2026."},{"field":"ownership.direct","element":"directOrIndirectOwnership","label":"F2","text":"Pursuant to an agreement with OrbiMed Advisors LLC, the Reporting Person is obligated to transfer any securities issued under any such stock options or other awards, or the economic benefit thereof to OrbiMed Advisors LLC, which will in turn ensure that such securities or economic benefits are provided to OrbiMed Private Investments VIII, LP."}],"balance_after":23904,"derivative":{"exercise_price":16,"expiration_date":"2036-08-05","underlying":"Common Stock","underlying_shares":23904},"source":{"system":"sec-edgar","filing":"0001282930-26-000008","document":"form4-08102026_100839.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1839970/000128293026000008/form4-08102026_100839.xml","form_type":"4"}},{"id":691967,"issuer":{"id":5423,"kind":"organization","name":"BlossomHill Therapeutics, Inc."},"owners":[{"id":25044,"kind":"person","name":"Chen Bihua","position":1,"cik":"0001599214","reported_name":"Chen Bihua","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":25045,"kind":"organization","name":"Cormorant Asset Management, LP","position":2,"cik":"0001583977","reported_name":"Cormorant Asset Management, LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":25046,"kind":"organization","name":"Cormorant Global Healthcare Master Fund, LP","position":3,"cik":"0001618442","reported_name":"Cormorant Global Healthcare Master Fund, LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":25047,"kind":"organization","name":"Cormorant Private Healthcare Fund III LP","position":4,"cik":"0001817320","reported_name":"Cormorant Private Healthcare Fund III LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":25048,"kind":"organization","name":"Cormorant Private Healthcare Fund V LP","position":5,"cik":"0001969296","reported_name":"Cormorant Private Healthcare Fund V LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":25049,"kind":"organization","name":"Cormorant Private Healthcare Fund VI, LP","position":6,"cik":"0002098185","reported_name":"Cormorant Private Healthcare Fund VI, LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Series B Preferred Stock","published_at":"2026-08-10T22:32:08.000Z","date":"2026-08-10","kind":"exercise","planned":false,"acquired":false,"shares":1701541,"ownership":{"direct":false,"nature":"See footnotes"},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F2","text":"Each share of Series A Preferred Stock and Series B Preferred Stock (together, the \"Preferred Stock\") automatically converted into 1 share of Common Stock upon the closing of the Issuer's initial public offering without payment of further consideration. The Preferred Stock had no expiration date."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"Each share of Series A Preferred Stock and Series B Preferred Stock (together, the \"Preferred Stock\") automatically converted into 1 share of Common Stock upon the closing of the Issuer's initial public offering without payment of further consideration. The Preferred Stock had no expiration date."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"Each share of Series A Preferred Stock and Series B Preferred Stock (together, the \"Preferred Stock\") automatically converted into 1 share of Common Stock upon the closing of the Issuer's initial public offering without payment of further consideration. The Preferred Stock had no expiration date."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F2","text":"Each share of Series A Preferred Stock and Series B Preferred Stock (together, the \"Preferred Stock\") automatically converted into 1 share of Common Stock upon the closing of the Issuer's initial public offering without payment of further consideration. The Preferred Stock had no expiration date."},{"field":"derivative.underlying_shares","element":"underlyingSecurityShares","label":"F5","text":"Represents (i) 274,912 shares issued upon conversion of shares of Series B Preferred Stock beneficially owned by Master Fund, (ii) 1,052,460 shares issued upon conversion of shares of Series B Preferred Stock beneficially owned by Fund V and (iii) 374,169 shares issued upon conversion of shares of Series B Preferred Stock beneficially owned by Fund VI."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"Cormorant Asset Management, LP (\"Cormorant\") serves as the investment manager of Cormorant Global Healthcare Master Fund, LP (the \"Master Fund\"), Cormorant Private Healthcare Fund III, LP (\"Fund III\"), Cormorant Private Healthcare Fund V, LP (\"Fund V\") and Cormorant Private Healthcare Fund VI, LP (\"Fund VI\"). Cormorant Global Healthcare GP, LLC (\"GP LLC\"), Cormorant Private Healthcare GP III, LLC (\"GP III\"), Cormorant Private Healthcare GP V, LLC (\"GP V\") and Cormorant Private Healthcare GP VI, LLC\n(\"GP VI\") serve as General Partner of the Master Fund, Fund III, Fund V and Fund VI, respectively."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F4","text":"Bihua Chen serves as manager of Cormorant, GP LLC, GP III, GP V and GP VI. Each of the Reporting Persons disclaims beneficial ownership of the shares reported herein except to the extent of its or her pecuniary interest therein, and the filing of this Form 4 shall not be construed as an admission that any of the Reporting Persons is the beneficial owner of any such shares for purposes of Section 16(a) of the Securities Exchange Act of 1934 or for any other purpose."}],"balance_after":0,"derivative":{"underlying":"Common Stock","underlying_shares":1701541},"source":{"system":"sec-edgar","filing":"0001231919-26-000852","document":"form4-08102026_100859.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":6,"url":"https://www.sec.gov/Archives/edgar/data/1839970/000123191926000852/form4-08102026_100859.xml","form_type":"4"}},{"id":691966,"issuer":{"id":5423,"kind":"organization","name":"BlossomHill Therapeutics, Inc."},"owners":[{"id":25044,"kind":"person","name":"Chen Bihua","position":1,"cik":"0001599214","reported_name":"Chen Bihua","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":25045,"kind":"organization","name":"Cormorant Asset Management, LP","position":2,"cik":"0001583977","reported_name":"Cormorant Asset Management, LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":25046,"kind":"organization","name":"Cormorant Global Healthcare Master Fund, LP","position":3,"cik":"0001618442","reported_name":"Cormorant Global Healthcare Master Fund, LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":25047,"kind":"organization","name":"Cormorant Private Healthcare Fund III LP","position":4,"cik":"0001817320","reported_name":"Cormorant Private Healthcare Fund III LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":25048,"kind":"organization","name":"Cormorant Private Healthcare Fund V LP","position":5,"cik":"0001969296","reported_name":"Cormorant Private Healthcare Fund V LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":25049,"kind":"organization","name":"Cormorant Private Healthcare Fund VI, LP","position":6,"cik":"0002098185","reported_name":"Cormorant Private Healthcare Fund VI, LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Series A Preferred Stock","published_at":"2026-08-10T22:32:08.000Z","date":"2026-08-10","kind":"exercise","planned":false,"acquired":false,"shares":1599993,"ownership":{"direct":false,"nature":"See footnotes"},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F2","text":"Each share of Series A Preferred Stock and Series B Preferred Stock (together, the \"Preferred Stock\") automatically converted into 1 share of Common Stock upon the closing of the Issuer's initial public offering without payment of further consideration. The Preferred Stock had no expiration date."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"Each share of Series A Preferred Stock and Series B Preferred Stock (together, the \"Preferred Stock\") automatically converted into 1 share of Common Stock upon the closing of the Issuer's initial public offering without payment of further consideration. The Preferred Stock had no expiration date."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"Each share of Series A Preferred Stock and Series B Preferred Stock (together, the \"Preferred Stock\") automatically converted into 1 share of Common Stock upon the closing of the Issuer's initial public offering without payment of further consideration. The Preferred Stock had no expiration date."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F2","text":"Each share of Series A Preferred Stock and Series B Preferred Stock (together, the \"Preferred Stock\") automatically converted into 1 share of Common Stock upon the closing of the Issuer's initial public offering without payment of further consideration. The Preferred Stock had no expiration date."},{"field":"derivative.underlying_shares","element":"underlyingSecurityShares","label":"F1","text":"Represents (i) 1,228,315 shares issued upon conversion of shares of Series A Preferred Stock beneficially owned by Fund III (defined below), and (ii) 371,678 shares issued upon conversion of shares of Series A Preferred Stock beneficially owned by Master Fund (defined below)."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"Cormorant Asset Management, LP (\"Cormorant\") serves as the investment manager of Cormorant Global Healthcare Master Fund, LP (the \"Master Fund\"), Cormorant Private Healthcare Fund III, LP (\"Fund III\"), Cormorant Private Healthcare Fund V, LP (\"Fund V\") and Cormorant Private Healthcare Fund VI, LP (\"Fund VI\"). Cormorant Global Healthcare GP, LLC (\"GP LLC\"), Cormorant Private Healthcare GP III, LLC (\"GP III\"), Cormorant Private Healthcare GP V, LLC (\"GP V\") and Cormorant Private Healthcare GP VI, LLC\n(\"GP VI\") serve as General Partner of the Master Fund, Fund III, Fund V and Fund VI, respectively."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F4","text":"Bihua Chen serves as manager of Cormorant, GP LLC, GP III, GP V and GP VI. Each of the Reporting Persons disclaims beneficial ownership of the shares reported herein except to the extent of its or her pecuniary interest therein, and the filing of this Form 4 shall not be construed as an admission that any of the Reporting Persons is the beneficial owner of any such shares for purposes of Section 16(a) of the Securities Exchange Act of 1934 or for any other purpose."}],"balance_after":0,"derivative":{"underlying":"Common Stock","underlying_shares":1599993},"source":{"system":"sec-edgar","filing":"0001231919-26-000852","document":"form4-08102026_100859.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/1839970/000123191926000852/form4-08102026_100859.xml","form_type":"4"}},{"id":691965,"issuer":{"id":5423,"kind":"organization","name":"BlossomHill Therapeutics, Inc."},"owners":[{"id":25044,"kind":"person","name":"Chen Bihua","position":1,"cik":"0001599214","reported_name":"Chen Bihua","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":25045,"kind":"organization","name":"Cormorant Asset Management, LP","position":2,"cik":"0001583977","reported_name":"Cormorant Asset Management, LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":25046,"kind":"organization","name":"Cormorant Global Healthcare Master Fund, LP","position":3,"cik":"0001618442","reported_name":"Cormorant Global Healthcare Master Fund, LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":25047,"kind":"organization","name":"Cormorant Private Healthcare Fund III LP","position":4,"cik":"0001817320","reported_name":"Cormorant Private Healthcare Fund III LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":25048,"kind":"organization","name":"Cormorant Private Healthcare Fund V LP","position":5,"cik":"0001969296","reported_name":"Cormorant Private Healthcare Fund V LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":25049,"kind":"organization","name":"Cormorant Private Healthcare Fund VI, LP","position":6,"cik":"0002098185","reported_name":"Cormorant Private Healthcare Fund VI, LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Director Stock Option (Right to Buy)","published_at":"2026-08-10T22:32:08.000Z","date":"2026-08-06","kind":"grant","planned":false,"acquired":true,"shares":23904,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F9","text":"1/36th of the shares subject to the option shall vest in equal monthly installments over a three year period following August 6, 2026."}],"balance_after":23904,"derivative":{"exercise_price":16,"expiration_date":"2036-08-05","underlying":"Common Stock","underlying_shares":23904},"source":{"system":"sec-edgar","filing":"0001231919-26-000852","document":"form4-08102026_100859.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1839970/000123191926000852/form4-08102026_100859.xml","form_type":"4"}},{"id":691964,"issuer":{"id":5423,"kind":"organization","name":"BlossomHill Therapeutics, Inc."},"owners":[{"id":25044,"kind":"person","name":"Chen Bihua","position":1,"cik":"0001599214","reported_name":"Chen Bihua","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":25045,"kind":"organization","name":"Cormorant Asset Management, LP","position":2,"cik":"0001583977","reported_name":"Cormorant Asset Management, LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":25046,"kind":"organization","name":"Cormorant Global Healthcare Master Fund, LP","position":3,"cik":"0001618442","reported_name":"Cormorant Global Healthcare Master Fund, LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":25047,"kind":"organization","name":"Cormorant Private Healthcare Fund III LP","position":4,"cik":"0001817320","reported_name":"Cormorant Private Healthcare Fund III LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":25048,"kind":"organization","name":"Cormorant Private Healthcare Fund V LP","position":5,"cik":"0001969296","reported_name":"Cormorant Private Healthcare Fund V LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":25049,"kind":"organization","name":"Cormorant Private Healthcare Fund VI, LP","position":6,"cik":"0002098185","reported_name":"Cormorant Private Healthcare Fund VI, LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2026-08-10T22:32:08.000Z","date":"2026-08-10","kind":"purchase","planned":false,"acquired":true,"shares":312500,"price":16,"value":5000000.0,"ownership":{"direct":false,"nature":"See footnotes"},"footnotes":[{"field":"shares","element":"transactionShares","label":"F7","text":"The shares purchased are beneficially owned by Master Fund."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F8","text":"Represents an aggregate of (i) 959,090 shares beneficially owned by Master Fund, (ii) 1,228,315 shares beneficially owned by Fund III, (iii) 1,052,460 shares beneficially owned by Fund V, and (vi) 374,169 beneficially owned by Fund VI."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"Cormorant Asset Management, LP (\"Cormorant\") serves as the investment manager of Cormorant Global Healthcare Master Fund, LP (the \"Master Fund\"), Cormorant Private Healthcare Fund III, LP (\"Fund III\"), Cormorant Private Healthcare Fund V, LP (\"Fund V\") and Cormorant Private Healthcare Fund VI, LP (\"Fund VI\"). Cormorant Global Healthcare GP, LLC (\"GP LLC\"), Cormorant Private Healthcare GP III, LLC (\"GP III\"), Cormorant Private Healthcare GP V, LLC (\"GP V\") and Cormorant Private Healthcare GP VI, LLC\n(\"GP VI\") serve as General Partner of the Master Fund, Fund III, Fund V and Fund VI, respectively."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F4","text":"Bihua Chen serves as manager of Cormorant, GP LLC, GP III, GP V and GP VI. Each of the Reporting Persons disclaims beneficial ownership of the shares reported herein except to the extent of its or her pecuniary interest therein, and the filing of this Form 4 shall not be construed as an admission that any of the Reporting Persons is the beneficial owner of any such shares for purposes of Section 16(a) of the Securities Exchange Act of 1934 or for any other purpose."}],"balance_after":3614034,"source":{"system":"sec-edgar","filing":"0001231919-26-000852","document":"form4-08102026_100859.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1839970/000123191926000852/form4-08102026_100859.xml","form_type":"4"}},{"id":691963,"issuer":{"id":5423,"kind":"organization","name":"BlossomHill Therapeutics, Inc."},"owners":[{"id":25044,"kind":"person","name":"Chen Bihua","position":1,"cik":"0001599214","reported_name":"Chen Bihua","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":25045,"kind":"organization","name":"Cormorant Asset Management, LP","position":2,"cik":"0001583977","reported_name":"Cormorant Asset Management, LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":25046,"kind":"organization","name":"Cormorant Global Healthcare Master Fund, LP","position":3,"cik":"0001618442","reported_name":"Cormorant Global Healthcare Master Fund, LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":25047,"kind":"organization","name":"Cormorant Private Healthcare Fund III LP","position":4,"cik":"0001817320","reported_name":"Cormorant Private Healthcare Fund III LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":25048,"kind":"organization","name":"Cormorant Private Healthcare Fund V LP","position":5,"cik":"0001969296","reported_name":"Cormorant Private Healthcare Fund V LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":25049,"kind":"organization","name":"Cormorant Private Healthcare Fund VI, LP","position":6,"cik":"0002098185","reported_name":"Cormorant Private Healthcare Fund VI, LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2026-08-10T22:32:08.000Z","date":"2026-08-10","kind":"exercise","planned":false,"acquired":true,"shares":1701541,"ownership":{"direct":false,"nature":"See footnotes"},"footnotes":[{"field":"shares","element":"transactionShares","label":"F5","text":"Represents (i) 274,912 shares issued upon conversion of shares of Series B Preferred Stock beneficially owned by Master Fund, (ii) 1,052,460 shares issued upon conversion of shares of Series B Preferred Stock beneficially owned by Fund V and (iii) 374,169 shares issued upon conversion of shares of Series B Preferred Stock beneficially owned by Fund VI."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"Each share of Series A Preferred Stock and Series B Preferred Stock (together, the \"Preferred Stock\") automatically converted into 1 share of Common Stock upon the closing of the Issuer's initial public offering without payment of further consideration. The Preferred Stock had no expiration date."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F6","text":"Represents an aggregate of (i) 646,590 shares beneficially owned by Master Fund, (ii) 1,228,315 shares beneficially owned by Fund III, (iii) 1,052,460 shares beneficially owned by Fund V, and (vi) 374,169 beneficially owned by Fund VI."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"Cormorant Asset Management, LP (\"Cormorant\") serves as the investment manager of Cormorant Global Healthcare Master Fund, LP (the \"Master Fund\"), Cormorant Private Healthcare Fund III, LP (\"Fund III\"), Cormorant Private Healthcare Fund V, LP (\"Fund V\") and Cormorant Private Healthcare Fund VI, LP (\"Fund VI\"). Cormorant Global Healthcare GP, LLC (\"GP LLC\"), Cormorant Private Healthcare GP III, LLC (\"GP III\"), Cormorant Private Healthcare GP V, LLC (\"GP V\") and Cormorant Private Healthcare GP VI, LLC\n(\"GP VI\") serve as General Partner of the Master Fund, Fund III, Fund V and Fund VI, respectively."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F4","text":"Bihua Chen serves as manager of Cormorant, GP LLC, GP III, GP V and GP VI. Each of the Reporting Persons disclaims beneficial ownership of the shares reported herein except to the extent of its or her pecuniary interest therein, and the filing of this Form 4 shall not be construed as an admission that any of the Reporting Persons is the beneficial owner of any such shares for purposes of Section 16(a) of the Securities Exchange Act of 1934 or for any other purpose."}],"balance_after":3301534,"source":{"system":"sec-edgar","filing":"0001231919-26-000852","document":"form4-08102026_100859.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1839970/000123191926000852/form4-08102026_100859.xml","form_type":"4"}},{"id":691962,"issuer":{"id":5423,"kind":"organization","name":"BlossomHill Therapeutics, Inc."},"owners":[{"id":25044,"kind":"person","name":"Chen Bihua","position":1,"cik":"0001599214","reported_name":"Chen Bihua","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":25045,"kind":"organization","name":"Cormorant Asset Management, LP","position":2,"cik":"0001583977","reported_name":"Cormorant Asset Management, LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":25046,"kind":"organization","name":"Cormorant Global Healthcare Master Fund, LP","position":3,"cik":"0001618442","reported_name":"Cormorant Global Healthcare Master Fund, LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":25047,"kind":"organization","name":"Cormorant Private Healthcare Fund III LP","position":4,"cik":"0001817320","reported_name":"Cormorant Private Healthcare Fund III LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":25048,"kind":"organization","name":"Cormorant Private Healthcare Fund V LP","position":5,"cik":"0001969296","reported_name":"Cormorant Private Healthcare Fund V LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":25049,"kind":"organization","name":"Cormorant Private Healthcare Fund VI, LP","position":6,"cik":"0002098185","reported_name":"Cormorant Private Healthcare Fund VI, LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2026-08-10T22:32:08.000Z","date":"2026-08-10","kind":"exercise","planned":false,"acquired":true,"shares":1599993,"ownership":{"direct":false,"nature":"See footnotes"},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Represents (i) 1,228,315 shares issued upon conversion of shares of Series A Preferred Stock beneficially owned by Fund III (defined below), and (ii) 371,678 shares issued upon conversion of shares of Series A Preferred Stock beneficially owned by Master Fund (defined below)."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"Each share of Series A Preferred Stock and Series B Preferred Stock (together, the \"Preferred Stock\") automatically converted into 1 share of Common Stock upon the closing of the Issuer's initial public offering without payment of further consideration. The Preferred Stock had no expiration date."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F1","text":"Represents (i) 1,228,315 shares issued upon conversion of shares of Series A Preferred Stock beneficially owned by Fund III (defined below), and (ii) 371,678 shares issued upon conversion of shares of Series A Preferred Stock beneficially owned by Master Fund (defined below)."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"Cormorant Asset Management, LP (\"Cormorant\") serves as the investment manager of Cormorant Global Healthcare Master Fund, LP (the \"Master Fund\"), Cormorant Private Healthcare Fund III, LP (\"Fund III\"), Cormorant Private Healthcare Fund V, LP (\"Fund V\") and Cormorant Private Healthcare Fund VI, LP (\"Fund VI\"). Cormorant Global Healthcare GP, LLC (\"GP LLC\"), Cormorant Private Healthcare GP III, LLC (\"GP III\"), Cormorant Private Healthcare GP V, LLC (\"GP V\") and Cormorant Private Healthcare GP VI, LLC\n(\"GP VI\") serve as General Partner of the Master Fund, Fund III, Fund V and Fund VI, respectively."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F4","text":"Bihua Chen serves as manager of Cormorant, GP LLC, GP III, GP V and GP VI. Each of the Reporting Persons disclaims beneficial ownership of the shares reported herein except to the extent of its or her pecuniary interest therein, and the filing of this Form 4 shall not be construed as an admission that any of the Reporting Persons is the beneficial owner of any such shares for purposes of Section 16(a) of the Securities Exchange Act of 1934 or for any other purpose."}],"balance_after":1599993,"source":{"system":"sec-edgar","filing":"0001231919-26-000852","document":"form4-08102026_100859.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1839970/000123191926000852/form4-08102026_100859.xml","form_type":"4"}},{"id":692461,"issuer":{"id":5423,"kind":"organization","name":"BlossomHill Therapeutics, Inc."},"owners":[{"id":25216,"kind":"person","name":"Agrawal Sundeep","position":1,"cik":"0001840599","reported_name":"Agrawal Sundeep","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Series B Preferred Stock","published_at":"2026-08-10T22:29:03.000Z","date":"2026-08-10","kind":"exercise","planned":false,"acquired":false,"shares":578524,"ownership":{"direct":false,"nature":"By Brahma BlossomHill Partners, LLC"},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"Each share of Series B Preferred Stock (the \"Preferred Stock\") automatically converted into 1 share of Common Stock upon the closing of the Issuer's initial public offering without payment of further consideration. The Preferred Stock had no expiration date."},{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Each share of Series B Preferred Stock (the \"Preferred Stock\") automatically converted into 1 share of Common Stock upon the closing of the Issuer's initial public offering without payment of further consideration. The Preferred Stock had no expiration date."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"Each share of Series B Preferred Stock (the \"Preferred Stock\") automatically converted into 1 share of Common Stock upon the closing of the Issuer's initial public offering without payment of further consideration. The Preferred Stock had no expiration date."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F1","text":"Each share of Series B Preferred Stock (the \"Preferred Stock\") automatically converted into 1 share of Common Stock upon the closing of the Issuer's initial public offering without payment of further consideration. The Preferred Stock had no expiration date."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"The securities are held of record by Brahma BlossomHill Partners, LLC (\"Brahma Partners\"). The Reporting Person is the founder and managing partner of Brahma Capital, LLC, which manages Brahma Partners, and may be deemed to have sole voting and/or investment power over the securities held by Brahma Partners. The Reporting Person disclaims beneficial ownership of these securities, and this report shall not be deemed an admission that the reporting person is the beneficial owner of the securities for purposes of Section 16 or for any other purpose."}],"balance_after":0,"derivative":{"underlying":"Common Stock","underlying_shares":578524},"source":{"system":"sec-edgar","filing":"0001840599-26-000003","document":"form4-08102026_100855.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1840599/000184059926000003/form4-08102026_100855.xml","form_type":"4"}},{"id":692460,"issuer":{"id":5423,"kind":"organization","name":"BlossomHill Therapeutics, Inc."},"owners":[{"id":25216,"kind":"person","name":"Agrawal Sundeep","position":1,"cik":"0001840599","reported_name":"Agrawal Sundeep","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Director Stock Option (Right to Buy)","published_at":"2026-08-10T22:29:03.000Z","date":"2026-08-06","kind":"grant","planned":false,"acquired":true,"shares":23904,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"1/36th of the shares subject to the option shall vest in equal monthly installments over a three year period following August 6, 2026."}],"balance_after":23904,"derivative":{"exercise_price":16,"expiration_date":"2036-08-05","underlying":"Common Stock","underlying_shares":23904},"source":{"system":"sec-edgar","filing":"0001840599-26-000003","document":"form4-08102026_100855.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1840599/000184059926000003/form4-08102026_100855.xml","form_type":"4"}},{"id":692459,"issuer":{"id":5423,"kind":"organization","name":"BlossomHill Therapeutics, Inc."},"owners":[{"id":25216,"kind":"person","name":"Agrawal Sundeep","position":1,"cik":"0001840599","reported_name":"Agrawal Sundeep","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2026-08-10T22:29:03.000Z","date":"2026-08-10","kind":"exercise","planned":false,"acquired":true,"shares":578524,"ownership":{"direct":false,"nature":"By Brahma BlossomHill Partners, LLC"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Each share of Series B Preferred Stock (the \"Preferred Stock\") automatically converted into 1 share of Common Stock upon the closing of the Issuer's initial public offering without payment of further consideration. The Preferred Stock had no expiration date."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"The securities are held of record by Brahma BlossomHill Partners, LLC (\"Brahma Partners\"). The Reporting Person is the founder and managing partner of Brahma Capital, LLC, which manages Brahma Partners, and may be deemed to have sole voting and/or investment power over the securities held by Brahma Partners. The Reporting Person disclaims beneficial ownership of these securities, and this report shall not be deemed an admission that the reporting person is the beneficial owner of the securities for purposes of Section 16 or for any other purpose."}],"balance_after":578524,"source":{"system":"sec-edgar","filing":"0001840599-26-000003","document":"form4-08102026_100855.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1840599/000184059926000003/form4-08102026_100855.xml","form_type":"4"}},{"id":691969,"issuer":{"id":5423,"kind":"organization","name":"BlossomHill Therapeutics, Inc."},"owners":[{"id":25050,"kind":"person","name":"Keyes Jason A","position":1,"cik":"0001678152","reported_name":"Keyes Jason A","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Employee Stock Option (Right to Buy)","published_at":"2026-08-10T22:27:21.000Z","date":"2026-08-06","kind":"grant","planned":false,"acquired":true,"shares":56746,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"1/4th of the shares subject to the option shall vest on August 6, 2027, and the balance of the shares shall vest in equal monthly installments over the following 36 months."}],"balance_after":56746,"derivative":{"exercise_price":16,"expiration_date":"2036-08-05","underlying":"Common Stock","underlying_shares":56746},"source":{"system":"sec-edgar","filing":"0001678152-26-000003","document":"form4-08102026_100815.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1839970/000167815226000003/form4-08102026_100815.xml","form_type":"4"}},{"id":691968,"issuer":{"id":5423,"kind":"organization","name":"BlossomHill Therapeutics, Inc."},"owners":[{"id":25050,"kind":"person","name":"Keyes Jason A","position":1,"cik":"0001678152","reported_name":"Keyes Jason A","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Common Stock","published_at":"2026-08-10T22:27:21.000Z","date":"2026-08-10","kind":"purchase","planned":false,"acquired":true,"shares":700,"price":16,"value":11200.0,"ownership":{"direct":true},"balance_after":700,"source":{"system":"sec-edgar","filing":"0001678152-26-000003","document":"form4-08102026_100815.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1839970/000167815226000003/form4-08102026_100815.xml","form_type":"4"}},{"id":691961,"issuer":{"id":5423,"kind":"organization","name":"BlossomHill Therapeutics, Inc."},"owners":[{"id":25043,"kind":"person","name":"Liptak Vincent Paul","position":1,"cik":"0002143905","reported_name":"Liptak Vincent Paul","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"General Counsel"}}],"security":"Series B Preferred Stock","published_at":"2026-08-10T22:26:05.000Z","date":"2026-08-10","kind":"exercise","planned":false,"acquired":false,"shares":22687,"ownership":{"direct":false,"nature":"By Walter T. Liptak Revocable Trust"},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"Each share of Series B Preferred Stock (the \"Preferred Stock\") automatically converted into 1 share of Common Stock upon the closing of the Issuer's initial public offering without payment of further consideration. The Preferred Stock had no expiration date."},{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Each share of Series B Preferred Stock (the \"Preferred Stock\") automatically converted into 1 share of Common Stock upon the closing of the Issuer's initial public offering without payment of further consideration. The Preferred Stock had no expiration date."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"Each share of Series B Preferred Stock (the \"Preferred Stock\") automatically converted into 1 share of Common Stock upon the closing of the Issuer's initial public offering without payment of further consideration. The Preferred Stock had no expiration date."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F1","text":"Each share of Series B Preferred Stock (the \"Preferred Stock\") automatically converted into 1 share of Common Stock upon the closing of the Issuer's initial public offering without payment of further consideration. The Preferred Stock had no expiration date."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"The Reporting Person is a co-beneficiary and co-trustee of the Walter T. Liptak Revocable Trust (the \"Trust\") and has voting and dispositive power over the securities held by the Trust."}],"balance_after":0,"derivative":{"underlying":"Common Stock","underlying_shares":22687},"source":{"system":"sec-edgar","filing":"0002143905-26-000003","document":"form4-08102026_100801.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/1839970/000214390526000003/form4-08102026_100801.xml","form_type":"4"}},{"id":691960,"issuer":{"id":5423,"kind":"organization","name":"BlossomHill Therapeutics, Inc."},"owners":[{"id":25043,"kind":"person","name":"Liptak Vincent Paul","position":1,"cik":"0002143905","reported_name":"Liptak Vincent Paul","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"General Counsel"}}],"security":"Employee Stock Option (Right to Buy)","published_at":"2026-08-10T22:26:05.000Z","date":"2026-08-06","kind":"grant","planned":false,"acquired":true,"shares":46561,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"1/4th of the shares subject to the option shall vest on August 6, 2027, and the balance of the shares shall vest in equal monthly installments over the following 36 months."}],"balance_after":46561,"derivative":{"exercise_price":16,"expiration_date":"2036-08-05","underlying":"Common Stock","underlying_shares":46561},"source":{"system":"sec-edgar","filing":"0002143905-26-000003","document":"form4-08102026_100801.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1839970/000214390526000003/form4-08102026_100801.xml","form_type":"4"}},{"id":691959,"issuer":{"id":5423,"kind":"organization","name":"BlossomHill Therapeutics, Inc."},"owners":[{"id":25043,"kind":"person","name":"Liptak Vincent Paul","position":1,"cik":"0002143905","reported_name":"Liptak Vincent Paul","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"General Counsel"}}],"security":"Common Stock","published_at":"2026-08-10T22:26:05.000Z","date":"2026-08-10","kind":"exercise","planned":false,"acquired":true,"shares":22687,"ownership":{"direct":false,"nature":"By Walter T. Liptak Revocable Trust"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Each share of Series B Preferred Stock (the \"Preferred Stock\") automatically converted into 1 share of Common Stock upon the closing of the Issuer's initial public offering without payment of further consideration. The Preferred Stock had no expiration date."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"The Reporting Person is a co-beneficiary and co-trustee of the Walter T. Liptak Revocable Trust (the \"Trust\") and has voting and dispositive power over the securities held by the Trust."}],"balance_after":22687,"source":{"system":"sec-edgar","filing":"0002143905-26-000003","document":"form4-08102026_100801.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1839970/000214390526000003/form4-08102026_100801.xml","form_type":"4"}},{"id":691958,"issuer":{"id":5423,"kind":"organization","name":"BlossomHill Therapeutics, Inc."},"owners":[{"id":25043,"kind":"person","name":"Liptak Vincent Paul","position":1,"cik":"0002143905","reported_name":"Liptak Vincent Paul","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"General Counsel"}}],"security":"Common Stock","published_at":"2026-08-10T22:26:05.000Z","date":"2026-08-10","kind":"purchase","planned":false,"acquired":true,"shares":2200,"price":16,"value":35200.0,"ownership":{"direct":true},"balance_after":111412,"source":{"system":"sec-edgar","filing":"0002143905-26-000003","document":"form4-08102026_100801.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1839970/000214390526000003/form4-08102026_100801.xml","form_type":"4"}},{"id":691957,"issuer":{"id":5423,"kind":"organization","name":"BlossomHill Therapeutics, Inc."},"owners":[{"id":25043,"kind":"person","name":"Liptak Vincent Paul","position":1,"cik":"0002143905","reported_name":"Liptak Vincent Paul","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"General Counsel"}}],"security":"Common Stock","published_at":"2026-08-10T22:26:05.000Z","date":"2026-08-07","kind":"purchase","planned":false,"acquired":true,"shares":2500,"price":15.8,"value":39500.0,"ownership":{"direct":true},"balance_after":109212,"source":{"system":"sec-edgar","filing":"0002143905-26-000003","document":"form4-08102026_100801.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1839970/000214390526000003/form4-08102026_100801.xml","form_type":"4"}},{"id":691956,"issuer":{"id":5423,"kind":"organization","name":"BlossomHill Therapeutics, Inc."},"owners":[{"id":25042,"kind":"person","name":"Oxnard Geoffrey Raymond","position":1,"cik":"0002144320","reported_name":"Oxnard Geoffrey Raymond","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Medical Officer"}}],"security":"Employee Stock Option (Right to Buy)","published_at":"2026-08-10T22:24:51.000Z","date":"2026-08-06","kind":"grant","planned":false,"acquired":true,"shares":61783,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"1/4th of the shares subject to the option shall vest on August 6, 2027, and the balance of the shares shall vest in equal monthly installments over the following 36 months."}],"balance_after":61783,"derivative":{"exercise_price":16,"expiration_date":"2036-08-05","underlying":"Common Stock","underlying_shares":61783},"source":{"system":"sec-edgar","filing":"0002144320-26-000003","document":"form4-08102026_100847.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1839970/000214432026000003/form4-08102026_100847.xml","form_type":"4"}},{"id":691955,"issuer":{"id":5423,"kind":"organization","name":"BlossomHill Therapeutics, Inc."},"owners":[{"id":25041,"kind":"person","name":"Li Yishan","position":1,"cik":"0001772233","reported_name":"Li Yishan","relationship":{"director":true,"officer":true,"ten_percent_owner":true,"other":false,"officer_title":"Executive Chairman"}}],"security":"Series B Preferred Stock","published_at":"2026-08-10T22:23:18.000Z","date":"2026-08-10","kind":"exercise","planned":false,"acquired":false,"shares":124779,"ownership":{"direct":false,"nature":"By RongShan, LLC"},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"Each share of Series Angel Preferred Stock and Series B Preferred Stock (together, the \"Preferred Stock\") automatically converted into 1 share of Common Stock upon the closing of the Issuer's initial public offering without payment of further consideration. The Preferred Stock had no expiration date."},{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Each share of Series Angel Preferred Stock and Series B Preferred Stock (together, the \"Preferred Stock\") automatically converted into 1 share of Common Stock upon the closing of the Issuer's initial public offering without payment of further consideration. The Preferred Stock had no expiration date."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"Each share of Series Angel Preferred Stock and Series B Preferred Stock (together, the \"Preferred Stock\") automatically converted into 1 share of Common Stock upon the closing of the Issuer's initial public offering without payment of further consideration. The Preferred Stock had no expiration date."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F1","text":"Each share of Series Angel Preferred Stock and Series B Preferred Stock (together, the \"Preferred Stock\") automatically converted into 1 share of Common Stock upon the closing of the Issuer's initial public offering without payment of further consideration. The Preferred Stock had no expiration date."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"The Reporting Person is manager of RongShan, LLC and may be deemed to have voting and dispositive power over the securities held by RongShan.LLC. The Reporting Person disclaims beneficial ownership of these securities, and this report shall not be deemed an\nadmission that the Reporting Person is the beneficial owner of the securities for purposes of Section 16 or for any other purpose."}],"balance_after":0,"derivative":{"underlying":"Common Stock","underlying_shares":124779},"source":{"system":"sec-edgar","filing":"0001772233-26-000005","document":"form4-08102026_100812.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":9,"url":"https://www.sec.gov/Archives/edgar/data/1839970/000177223326000005/form4-08102026_100812.xml","form_type":"4"}},{"id":691954,"issuer":{"id":5423,"kind":"organization","name":"BlossomHill Therapeutics, Inc."},"owners":[{"id":25041,"kind":"person","name":"Li Yishan","position":1,"cik":"0001772233","reported_name":"Li Yishan","relationship":{"director":true,"officer":true,"ten_percent_owner":true,"other":false,"officer_title":"Executive Chairman"}}],"security":"Series B Preferred Stock","published_at":"2026-08-10T22:23:18.000Z","date":"2026-08-10","kind":"exercise","planned":false,"acquired":false,"shares":113435,"ownership":{"direct":false,"nature":"By The Li and Cui Family Trust"},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"Each share of Series Angel Preferred Stock and Series B Preferred Stock (together, the \"Preferred Stock\") automatically converted into 1 share of Common Stock upon the closing of the Issuer's initial public offering without payment of further consideration. The Preferred Stock had no expiration date."},{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Each share of Series Angel Preferred Stock and Series B Preferred Stock (together, the \"Preferred Stock\") automatically converted into 1 share of Common Stock upon the closing of the Issuer's initial public offering without payment of further consideration. The Preferred Stock had no expiration date."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"Each share of Series Angel Preferred Stock and Series B Preferred Stock (together, the \"Preferred Stock\") automatically converted into 1 share of Common Stock upon the closing of the Issuer's initial public offering without payment of further consideration. The Preferred Stock had no expiration date."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F1","text":"Each share of Series Angel Preferred Stock and Series B Preferred Stock (together, the \"Preferred Stock\") automatically converted into 1 share of Common Stock upon the closing of the Issuer's initial public offering without payment of further consideration. The Preferred Stock had no expiration date."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"The shares are held in trust for the benefit of the Reporting Person and his spouse. The Reporting Person and his spouse are trustees of The Li and Cui Family Trust (the \"Trust\") and have voting and dispositive power over the securities held by the Trust."}],"balance_after":0,"derivative":{"underlying":"Common Stock","underlying_shares":113435},"source":{"system":"sec-edgar","filing":"0001772233-26-000005","document":"form4-08102026_100812.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":8,"url":"https://www.sec.gov/Archives/edgar/data/1839970/000177223326000005/form4-08102026_100812.xml","form_type":"4"}},{"id":691953,"issuer":{"id":5423,"kind":"organization","name":"BlossomHill Therapeutics, Inc."},"owners":[{"id":25041,"kind":"person","name":"Li Yishan","position":1,"cik":"0001772233","reported_name":"Li Yishan","relationship":{"director":true,"officer":true,"ten_percent_owner":true,"other":false,"officer_title":"Executive Chairman"}}],"security":"Series Angel Preferred Stock","published_at":"2026-08-10T22:23:18.000Z","date":"2026-08-10","kind":"exercise","planned":false,"acquired":false,"shares":1600682,"ownership":{"direct":false,"nature":"By The Li and Cui Family Trust"},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"Each share of Series Angel Preferred Stock and Series B Preferred Stock (together, the \"Preferred Stock\") automatically converted into 1 share of Common Stock upon the closing of the Issuer's initial public offering without payment of further consideration. The Preferred Stock had no expiration date."},{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Each share of Series Angel Preferred Stock and Series B Preferred Stock (together, the \"Preferred Stock\") automatically converted into 1 share of Common Stock upon the closing of the Issuer's initial public offering without payment of further consideration. The Preferred Stock had no expiration date."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"Each share of Series Angel Preferred Stock and Series B Preferred Stock (together, the \"Preferred Stock\") automatically converted into 1 share of Common Stock upon the closing of the Issuer's initial public offering without payment of further consideration. The Preferred Stock had no expiration date."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F1","text":"Each share of Series Angel Preferred Stock and Series B Preferred Stock (together, the \"Preferred Stock\") automatically converted into 1 share of Common Stock upon the closing of the Issuer's initial public offering without payment of further consideration. The Preferred Stock had no expiration date."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"The shares are held in trust for the benefit of the Reporting Person and his spouse. The Reporting Person and his spouse are trustees of The Li and Cui Family Trust (the \"Trust\") and have voting and dispositive power over the securities held by the Trust."}],"balance_after":0,"derivative":{"underlying":"Common Stock","underlying_shares":1600682},"source":{"system":"sec-edgar","filing":"0001772233-26-000005","document":"form4-08102026_100812.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":7,"url":"https://www.sec.gov/Archives/edgar/data/1839970/000177223326000005/form4-08102026_100812.xml","form_type":"4"}},{"id":691952,"issuer":{"id":5423,"kind":"organization","name":"BlossomHill Therapeutics, Inc."},"owners":[{"id":25041,"kind":"person","name":"Li Yishan","position":1,"cik":"0001772233","reported_name":"Li Yishan","relationship":{"director":true,"officer":true,"ten_percent_owner":true,"other":false,"officer_title":"Executive Chairman"}}],"security":"Employee Stock Option (Right to Buy)","published_at":"2026-08-10T22:23:18.000Z","date":"2026-08-06","kind":"grant","planned":false,"acquired":true,"shares":112701,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"1/4th of the shares subject to the option shall vest on August 6, 2027, and the balance of the shares shall vest in equal monthly installments over the following 36 months."}],"balance_after":112701,"derivative":{"exercise_price":16,"expiration_date":"2036-08-05","underlying":"Common Stock","underlying_shares":112701},"source":{"system":"sec-edgar","filing":"0001772233-26-000005","document":"form4-08102026_100812.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":6,"url":"https://www.sec.gov/Archives/edgar/data/1839970/000177223326000005/form4-08102026_100812.xml","form_type":"4"}},{"id":691951,"issuer":{"id":5423,"kind":"organization","name":"BlossomHill Therapeutics, Inc."},"owners":[{"id":25041,"kind":"person","name":"Li Yishan","position":1,"cik":"0001772233","reported_name":"Li Yishan","relationship":{"director":true,"officer":true,"ten_percent_owner":true,"other":false,"officer_title":"Executive Chairman"}}],"security":"Common Stock","published_at":"2026-08-10T22:23:18.000Z","date":"2026-08-10","kind":"exercise","planned":false,"acquired":true,"shares":124779,"ownership":{"direct":false,"nature":"By RongShan, LLC"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Each share of Series Angel Preferred Stock and Series B Preferred Stock (together, the \"Preferred Stock\") automatically converted into 1 share of Common Stock upon the closing of the Issuer's initial public offering without payment of further consideration. The Preferred Stock had no expiration date."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"The Reporting Person is manager of RongShan, LLC and may be deemed to have voting and dispositive power over the securities held by RongShan.LLC. The Reporting Person disclaims beneficial ownership of these securities, and this report shall not be deemed an\nadmission that the Reporting Person is the beneficial owner of the securities for purposes of Section 16 or for any other purpose."}],"balance_after":124779,"source":{"system":"sec-edgar","filing":"0001772233-26-000005","document":"form4-08102026_100812.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1839970/000177223326000005/form4-08102026_100812.xml","form_type":"4"}},{"id":691950,"issuer":{"id":5423,"kind":"organization","name":"BlossomHill Therapeutics, Inc."},"owners":[{"id":25041,"kind":"person","name":"Li Yishan","position":1,"cik":"0001772233","reported_name":"Li Yishan","relationship":{"director":true,"officer":true,"ten_percent_owner":true,"other":false,"officer_title":"Executive Chairman"}}],"security":"Common Stock","published_at":"2026-08-10T22:23:18.000Z","date":"2026-08-10","kind":"exercise","planned":false,"acquired":true,"shares":113435,"ownership":{"direct":false,"nature":"By The Li and Cui Family Trust"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Each share of Series Angel Preferred Stock and Series B Preferred Stock (together, the \"Preferred Stock\") automatically converted into 1 share of Common Stock upon the closing of the Issuer's initial public offering without payment of further consideration. The Preferred Stock had no expiration date."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"The shares are held in trust for the benefit of the Reporting Person and his spouse. The Reporting Person and his spouse are trustees of The Li and Cui Family Trust (the \"Trust\") and have voting and dispositive power over the securities held by the Trust."}],"balance_after":1714117,"source":{"system":"sec-edgar","filing":"0001772233-26-000005","document":"form4-08102026_100812.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1839970/000177223326000005/form4-08102026_100812.xml","form_type":"4"}},{"id":691949,"issuer":{"id":5423,"kind":"organization","name":"BlossomHill Therapeutics, Inc."},"owners":[{"id":25041,"kind":"person","name":"Li Yishan","position":1,"cik":"0001772233","reported_name":"Li Yishan","relationship":{"director":true,"officer":true,"ten_percent_owner":true,"other":false,"officer_title":"Executive Chairman"}}],"security":"Common Stock","published_at":"2026-08-10T22:23:18.000Z","date":"2026-08-10","kind":"exercise","planned":false,"acquired":true,"shares":1600682,"ownership":{"direct":false,"nature":"By The Li and Cui Family Trust"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Each share of Series Angel Preferred Stock and Series B Preferred Stock (together, the \"Preferred Stock\") automatically converted into 1 share of Common Stock upon the closing of the Issuer's initial public offering without payment of further consideration. The Preferred Stock had no expiration date."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"The shares are held in trust for the benefit of the Reporting Person and his spouse. The Reporting Person and his spouse are trustees of The Li and Cui Family Trust (the \"Trust\") and have voting and dispositive power over the securities held by the Trust."}],"balance_after":1600682,"source":{"system":"sec-edgar","filing":"0001772233-26-000005","document":"form4-08102026_100812.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1839970/000177223326000005/form4-08102026_100812.xml","form_type":"4"}},{"id":691948,"issuer":{"id":5423,"kind":"organization","name":"BlossomHill Therapeutics, Inc."},"owners":[{"id":25040,"kind":"person","name":"Cui Jingrong Jean","position":1,"cik":"0001772259","reported_name":"Cui Jingrong Jean","relationship":{"director":true,"officer":true,"ten_percent_owner":true,"other":false,"officer_title":"President and CEO"}}],"security":"Series B Preferred Stock","published_at":"2026-08-10T22:22:07.000Z","date":"2026-08-10","kind":"exercise","planned":false,"acquired":false,"shares":124779,"ownership":{"direct":false,"nature":"By RongShan, LLC"},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"Each share of Series Angel Preferred Stock and Series B Preferred Stock (together, the \"Preferred Stock\") automatically converted into 1 share of Common Stock upon the closing of the Issuer's initial public offering without payment of further consideration. The Preferred Stock had no expiration date."},{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Each share of Series Angel Preferred Stock and Series B Preferred Stock (together, the \"Preferred Stock\") automatically converted into 1 share of Common Stock upon the closing of the Issuer's initial public offering without payment of further consideration. The Preferred Stock had no expiration date."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"Each share of Series Angel Preferred Stock and Series B Preferred Stock (together, the \"Preferred Stock\") automatically converted into 1 share of Common Stock upon the closing of the Issuer's initial public offering without payment of further consideration. The Preferred Stock had no expiration date."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F1","text":"Each share of Series Angel Preferred Stock and Series B Preferred Stock (together, the \"Preferred Stock\") automatically converted into 1 share of Common Stock upon the closing of the Issuer's initial public offering without payment of further consideration. The Preferred Stock had no expiration date."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"The Reporting Person's spouse is the manager of RongShan, LLC. The Reporting Person disclaims beneficial ownership of these securities, and this report shall not be deemed an admission that the Reporting Person is the beneficial owner of the securities for purposes of\nSection 16 or for any other purpose."}],"balance_after":0,"derivative":{"underlying":"Common Stock","underlying_shares":124779},"source":{"system":"sec-edgar","filing":"0001772259-26-000005","document":"form4-08102026_100800.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":9,"url":"https://www.sec.gov/Archives/edgar/data/1839970/000177225926000005/form4-08102026_100800.xml","form_type":"4"}},{"id":691947,"issuer":{"id":5423,"kind":"organization","name":"BlossomHill Therapeutics, Inc."},"owners":[{"id":25040,"kind":"person","name":"Cui Jingrong Jean","position":1,"cik":"0001772259","reported_name":"Cui Jingrong Jean","relationship":{"director":true,"officer":true,"ten_percent_owner":true,"other":false,"officer_title":"President and CEO"}}],"security":"Series B Preferred Stock","published_at":"2026-08-10T22:22:07.000Z","date":"2026-08-10","kind":"exercise","planned":false,"acquired":false,"shares":113435,"ownership":{"direct":false,"nature":"By The Li and Cui Family Trust"},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"Each share of Series Angel Preferred Stock and Series B Preferred Stock (together, the \"Preferred Stock\") automatically converted into 1 share of Common Stock upon the closing of the Issuer's initial public offering without payment of further consideration. The Preferred Stock had no expiration date."},{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Each share of Series Angel Preferred Stock and Series B Preferred Stock (together, the \"Preferred Stock\") automatically converted into 1 share of Common Stock upon the closing of the Issuer's initial public offering without payment of further consideration. The Preferred Stock had no expiration date."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"Each share of Series Angel Preferred Stock and Series B Preferred Stock (together, the \"Preferred Stock\") automatically converted into 1 share of Common Stock upon the closing of the Issuer's initial public offering without payment of further consideration. The Preferred Stock had no expiration date."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F1","text":"Each share of Series Angel Preferred Stock and Series B Preferred Stock (together, the \"Preferred Stock\") automatically converted into 1 share of Common Stock upon the closing of the Issuer's initial public offering without payment of further consideration. The Preferred Stock had no expiration date."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"The shares are held in trust for the benefit of the Reporting Person and her spouse. The Reporting Person and her spouse are trustees of The Li and Cui Family Trust (the \"Trust\") and have voting and dispositive power over the securities held by the Trust."}],"balance_after":0,"derivative":{"underlying":"Common Stock","underlying_shares":113435},"source":{"system":"sec-edgar","filing":"0001772259-26-000005","document":"form4-08102026_100800.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":8,"url":"https://www.sec.gov/Archives/edgar/data/1839970/000177225926000005/form4-08102026_100800.xml","form_type":"4"}},{"id":691946,"issuer":{"id":5423,"kind":"organization","name":"BlossomHill Therapeutics, Inc."},"owners":[{"id":25040,"kind":"person","name":"Cui Jingrong Jean","position":1,"cik":"0001772259","reported_name":"Cui Jingrong Jean","relationship":{"director":true,"officer":true,"ten_percent_owner":true,"other":false,"officer_title":"President and CEO"}}],"security":"Series Angel Preferred Stock","published_at":"2026-08-10T22:22:07.000Z","date":"2026-08-10","kind":"exercise","planned":false,"acquired":false,"shares":1600682,"ownership":{"direct":false,"nature":"By The Li and Cui Family Trust"},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"Each share of Series Angel Preferred Stock and Series B Preferred Stock (together, the \"Preferred Stock\") automatically converted into 1 share of Common Stock upon the closing of the Issuer's initial public offering without payment of further consideration. The Preferred Stock had no expiration date."},{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Each share of Series Angel Preferred Stock and Series B Preferred Stock (together, the \"Preferred Stock\") automatically converted into 1 share of Common Stock upon the closing of the Issuer's initial public offering without payment of further consideration. The Preferred Stock had no expiration date."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"Each share of Series Angel Preferred Stock and Series B Preferred Stock (together, the \"Preferred Stock\") automatically converted into 1 share of Common Stock upon the closing of the Issuer's initial public offering without payment of further consideration. The Preferred Stock had no expiration date."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F1","text":"Each share of Series Angel Preferred Stock and Series B Preferred Stock (together, the \"Preferred Stock\") automatically converted into 1 share of Common Stock upon the closing of the Issuer's initial public offering without payment of further consideration. The Preferred Stock had no expiration date."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"The shares are held in trust for the benefit of the Reporting Person and her spouse. The Reporting Person and her spouse are trustees of The Li and Cui Family Trust (the \"Trust\") and have voting and dispositive power over the securities held by the Trust."}],"balance_after":0,"derivative":{"underlying":"Common Stock","underlying_shares":1600682},"source":{"system":"sec-edgar","filing":"0001772259-26-000005","document":"form4-08102026_100800.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":7,"url":"https://www.sec.gov/Archives/edgar/data/1839970/000177225926000005/form4-08102026_100800.xml","form_type":"4"}},{"id":691945,"issuer":{"id":5423,"kind":"organization","name":"BlossomHill Therapeutics, Inc."},"owners":[{"id":25040,"kind":"person","name":"Cui Jingrong Jean","position":1,"cik":"0001772259","reported_name":"Cui Jingrong Jean","relationship":{"director":true,"officer":true,"ten_percent_owner":true,"other":false,"officer_title":"President and CEO"}}],"security":"Employee Stock Option (Right to Buy)","published_at":"2026-08-10T22:22:07.000Z","date":"2026-08-06","kind":"grant","planned":false,"acquired":true,"shares":676205,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"1/4th of the shares subject to the option shall vest on August 6, 2027, and the balance of the shares shall vest in equal monthly installments over the following 36 months."}],"balance_after":676205,"derivative":{"exercise_price":16,"expiration_date":"2036-08-05","underlying":"Common Stock","underlying_shares":676205},"source":{"system":"sec-edgar","filing":"0001772259-26-000005","document":"form4-08102026_100800.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":6,"url":"https://www.sec.gov/Archives/edgar/data/1839970/000177225926000005/form4-08102026_100800.xml","form_type":"4"}},{"id":691944,"issuer":{"id":5423,"kind":"organization","name":"BlossomHill Therapeutics, Inc."},"owners":[{"id":25040,"kind":"person","name":"Cui Jingrong Jean","position":1,"cik":"0001772259","reported_name":"Cui Jingrong Jean","relationship":{"director":true,"officer":true,"ten_percent_owner":true,"other":false,"officer_title":"President and CEO"}}],"security":"Common Stock","published_at":"2026-08-10T22:22:07.000Z","date":"2026-08-10","kind":"exercise","planned":false,"acquired":true,"shares":124779,"ownership":{"direct":false,"nature":"By RongShan, LLC"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Each share of Series Angel Preferred Stock and Series B Preferred Stock (together, the \"Preferred Stock\") automatically converted into 1 share of Common Stock upon the closing of the Issuer's initial public offering without payment of further consideration. The Preferred Stock had no expiration date."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"The Reporting Person's spouse is the manager of RongShan, LLC. The Reporting Person disclaims beneficial ownership of these securities, and this report shall not be deemed an admission that the Reporting Person is the beneficial owner of the securities for purposes of\nSection 16 or for any other purpose."}],"balance_after":124779,"source":{"system":"sec-edgar","filing":"0001772259-26-000005","document":"form4-08102026_100800.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1839970/000177225926000005/form4-08102026_100800.xml","form_type":"4"}},{"id":691943,"issuer":{"id":5423,"kind":"organization","name":"BlossomHill Therapeutics, Inc."},"owners":[{"id":25040,"kind":"person","name":"Cui Jingrong Jean","position":1,"cik":"0001772259","reported_name":"Cui Jingrong Jean","relationship":{"director":true,"officer":true,"ten_percent_owner":true,"other":false,"officer_title":"President and CEO"}}],"security":"Common Stock","published_at":"2026-08-10T22:22:07.000Z","date":"2026-08-10","kind":"exercise","planned":false,"acquired":true,"shares":113435,"ownership":{"direct":false,"nature":"By The Li and Cui Family Trust"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Each share of Series Angel Preferred Stock and Series B Preferred Stock (together, the \"Preferred Stock\") automatically converted into 1 share of Common Stock upon the closing of the Issuer's initial public offering without payment of further consideration. The Preferred Stock had no expiration date."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"The shares are held in trust for the benefit of the Reporting Person and her spouse. The Reporting Person and her spouse are trustees of The Li and Cui Family Trust (the \"Trust\") and have voting and dispositive power over the securities held by the Trust."}],"balance_after":1714117,"source":{"system":"sec-edgar","filing":"0001772259-26-000005","document":"form4-08102026_100800.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1839970/000177225926000005/form4-08102026_100800.xml","form_type":"4"}},{"id":691942,"issuer":{"id":5423,"kind":"organization","name":"BlossomHill Therapeutics, Inc."},"owners":[{"id":25040,"kind":"person","name":"Cui Jingrong Jean","position":1,"cik":"0001772259","reported_name":"Cui Jingrong Jean","relationship":{"director":true,"officer":true,"ten_percent_owner":true,"other":false,"officer_title":"President and CEO"}}],"security":"Common Stock","published_at":"2026-08-10T22:22:07.000Z","date":"2026-08-10","kind":"exercise","planned":false,"acquired":true,"shares":1600682,"ownership":{"direct":false,"nature":"By The Li and Cui Family Trust"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Each share of Series Angel Preferred Stock and Series B Preferred Stock (together, the \"Preferred Stock\") automatically converted into 1 share of Common Stock upon the closing of the Issuer's initial public offering without payment of further consideration. The Preferred Stock had no expiration date."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"The shares are held in trust for the benefit of the Reporting Person and her spouse. The Reporting Person and her spouse are trustees of The Li and Cui Family Trust (the \"Trust\") and have voting and dispositive power over the securities held by the Trust."}],"balance_after":1600682,"source":{"system":"sec-edgar","filing":"0001772259-26-000005","document":"form4-08102026_100800.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1839970/000177225926000005/form4-08102026_100800.xml","form_type":"4"}}]}